A study analyzed differently expressed microRNAs (miRNAs) that may serve as therapeutic targets in diffuse large B-cell lymphoma (DLBCL). The results appeared in the journal Oncology Letters.
“Understanding the molecular mechanisms involved in DLBCL is important to identify new therapeutic targets. The present study aimed to screen and identified differentially expressed miRNAs between DLBCL and control [lymph node reactive hyperplasia (LRH)] groups, and to investigate whether miRNAs associated with DLBCL could serve as potential therapeutic targets,” the researchers wrote.
In total, this study consisted of five DLBCL experimental samples and five control samples obtained from fresh patient tissues. The samples were analyzed using miRNA microarray to identify differentially expressed miRNAs. Overall, 204 differential miRNAs were identified. Subsequently, the target genes of differential miRNAs were analyzed using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis. To validate the miRNA data, the researchers used reverse transcription-quantitative polymerase chain reaction (RT-qPCR), which was performed for eight differentially expressed miRNAs (miR-193a-3p, miR-19a-3p, miR-19b-3p, miR-370-3p, miR-1275, miR-490-5p, miR-630 and miR-665) along with DLBCL samples.
According to the results, the 204 miRNAs demonstrated differential expression, including 105 downregulated and 54 upregulated miRNAs. The researchers concluded that “these differentially expressed miRNAs may serve as therapeutic targets for improvement of therapeutic efficacy in DLBCL in the future.”